XML 56 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisitions, Investments, and Licenses (Tables)
3 Months Ended
Mar. 31, 2014
Business Acquisition [Line Items]  
Pro forma disclosure for acquisitions
The following table includes the pro forma results for the three months ended March 31, 2013 of the combined companies as though the acquisition of OPKO Renal and OPKO Biologics had been completed as of the beginning of the period presented.
 
March 31,
(In thousands)
2013
Revenues
$
31,376

Loss from continuing operations

Net loss
(41,379
)
Net loss attributable to common shareholders
(41,252
)
Basic and diluted loss from continued operations per share
0.11

Basic and diluted loss per share
$
(0.11
)
Maximum exposure of unconsolidated investments
The following table reflects our maximum exposure, accounting method, ownership interest and underlying equity in net assets of each of our unconsolidated investments as of March 31, 2014:
(Dollars in thousands, except per share prices)
Investee name
 
Year
invested
 
Accounting method
 
Ownership at
March 31, 2014
 
Investment
 
Underlying equity in net assets
 
Closing share price
at March 31, 2014
for investments
available for sale
Neovasc
 
2011
 
Equity method
 
6
%
 
3,798

 
1,558

 
 
 
Fabrus
 
2010
 
VIE, equity method
 
12
%
 
750

 
(362
)
 
 
 
RXi
 
2013
 
Equity method
 
17
%
 
15,000

 
1,841

 
 
 
Pharmasynthez
 
2013
 
Equity method
 
17
%
 
11,300

 
6,405

 
 
 
Zebra
 
2013
 
VIE, equity method
 
19
%
 
2,000

 
840

 
 
 
Cocrystal
 
2009
 
Equity method
 
16
%
 
5,476

 
20

 
 
 
Neovasc options
 
2011
 
Investment available for sale
 
N/A

 
925

 
 
 
CA
$
4.10

ChromaDex
 
2012
 
Investment available for sale
 
1
%
 
1,320

 
 
 
 
$
1.83

ARNO
 
2013
 
Investment available for sale
 
5
%
 
2,000

 
 
 
 
$
2.22

Cocrystal 10 yr warrants
 
2014
 
Investment available for sale
 
N/A

 
500

 
 
 
 
 
Plus unrealized gains on investments, options and warrants, net
 
13,120

 
 
 
 
 
Less accumulated losses in investees
 
(20,492
)
 
 
 
 
 
Total carrying value of equity method investees and investments, available for sale
 
$
35,697

 
 
 
 
 
Cytochroma and PROLOR [Member]
 
Business Acquisition [Line Items]  
Estimated fair value of the net assets acquired and liabilities assumed in the acquisition of at the date of acquisition
The following table summarizes the purchase price allocation and the fair value of the net assets acquired and liabilities assumed in the acquisitions of OPKO Renal and OPKO Biologics at the dates of acquisition. The purchase price allocation for OPKO Biologics is subject to change while contingencies that existed on the acquisition date are resolved:
(In thousands)
OPKO Renal
 
OPKO Biologics
Current assets (1)
$
1,224

 
$
21,500

Intangible assets:
 
 
 
In-process research and development
191,530

 
590,200

Patents
210

 

Total intangible assets
191,740

 
590,200

Goodwill
2,411

 
139,784

Property, plant and equipment
306

 
1,057

Other assets

 
371

Accounts payable and accrued expenses
(1,069
)
 
(9,866
)
Deferred tax liability

 
(156,403
)
Total purchase price
$
194,612

 
$
586,643

(1)Current assets include cash of $0.4 million and $20.5 million related to the OPKO Renal and OPKO Biologics acquisitions, respectively.
SciVac [Member]
 
Business Acquisition [Line Items]  
Summary of consolidated assets and non-recourse liabilities related to SciVac
The following table represents the consolidated assets and non-recourse liabilities related to SciVac as of March 31, 2014 and December 31, 2013. These assets are owned by, and these liabilities are obligations of, SciVac, not us.
(In thousands)
March 31,
2014
 
December 31,
2013
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
123

 
$
2

Accounts receivable, net
103

 
283

Inventories, net
1,704

 
1,696

Prepaid expenses and other current assets
337

 
218

Total current assets
2,267

 
2,199

Property, plant and equipment, net
1,441

 
1,374

Intangible assets, net
1,073

 
1,111

Goodwill
1,732

 
1,821

Other assets
268

 
261

Total assets
$
6,781

 
6,766

Liabilities
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
1,223

 
$
1,136

Accrued expenses
7,800

 
6,498

Notes payable
2,101

 
1,537

Total current liabilities
11,124

 
9,171

Other long-term liabilities
266

 
1,240

Total liabilities
$
11,390

 
$
10,411